The estimated Net Worth of Kevin Carl Pegels is at least $941 Tausend dollars as of 21 February 2023. Mr Pegels owns over 1,097 units of Illumina Inc stock worth over $941,093 and over the last 3 years he sold ILMN stock worth over $0.
Mr has made over 2 trades of the Illumina Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 1,097 units of ILMN stock worth $136,939 on 21 February 2023.
The largest trade he's ever made was exercising 1,097 units of Illumina Inc stock on 21 February 2023 worth over $136,939. On average, Mr trades about 216 units every 36 days since 2021. As of 21 February 2023 he still owns at least 7,539 units of Illumina Inc stock.
You can see the complete history of Mr Pegels stock trades at the bottom of the page.
Kevin Carl Pegels is the Chief of Global Operations at Illumina Inc.
Kevin's mailing address filed with the SEC is 5200 ILLUMINA WAY, , SAN DIEGO, CA, 92122.
Over the last 21 years, insiders at Illumina Inc have traded over $412,190,379 worth of Illumina Inc stock and bought 13,386 units worth $1,243,499 . The most active insiders traders include John Wendell Thompson, Jay T Flatley und Robert Nelsen. On average, Illumina Inc executives and independent directors trade stock every 5 days with the average trade being worth of $954,700. The most recent stock trade was executed by Jacob Thaysen on 22 February 2024, trading 7,330 units of ILMN stock currently worth $991,676.
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Illumina Inc executives and other stock owners filed with the SEC include: